Top

Pediatric Rheumatology

Published in:

Open Access 01-12-2012 | Short Report

Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases

Authors: Roberta Berard, Blair Whittemore, Rosie Scuccimarri

Published in: Pediatric Rheumatology | Issue 1/2012

Abstract

Background

Hemolytic anemia is a rare but reported side effect of intravenous immunoglobulin (IVIG) therapy. The risk of significant hemolysis appears greater in those patients who receive high dose IVIG. The etiology is multifactorial but may relate to the quantity of blood group antibodies administered via the IVIG product.

Findings

We describe 4 patients with significant hemolytic anemia following treatment with IVIG for Kawasaki disease (KD). Direct antibody mediated attack as one of the mechanisms for hemolysis, in this population, is supported by the demonstration of specific blood group antibodies in addition to a positive direct antiglobulin test in our patients.

Conclusions

Clinicians should be aware of this complication and hemoglobin should be closely monitored following high dose IVIG therapy.

Burns JC, Mason WH, Hauger SB: Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005, 146: 662-667. 10.1016/j.jpeds.2004.12.022.CrossRefPubMed

Jolles S, Sewell WA, Misbah SA: Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005, 142: 1-11. 10.1111/j.1365-2249.2005.02834.x.PubMedCentralCrossRefPubMed

Knezevic-Maramica I, Kruskall MS: Intravenous immune globulins: an update for clinicians. Transfusion. 2003, 43: 1460-1480. 10.1046/j.1537-2995.2003.00519.x.CrossRefPubMed

Nagakawa M, Watanabe N, Okuno M: Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease. Am J Hematol. 2000, 63: 160-161. 10.1002/(SICI)1096-8652(200003)63:3<160::AID-AJH11>3.0.CO;2-4.CrossRef

Comenzo RL, Malachowski ME, Meissner HC: Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of IVIG for Kawasaki disease. J Pediatr. 1992, 120: 926-928. 10.1016/S0022-3476(05)81964-X.CrossRefPubMed

Hillyer CD, Schwenn MR, Fulton DR: Autoimmune hemolytic anemia in Kawasaki disease: a case report. Transfusion. 1990, 30: 738-740. 10.1046/j.1537-2995.1990.30891020336.x.CrossRefPubMed

Gordon DJ, Sloan SR, de Jong JLO: A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. Am J Hematol. 2009, 84 (11): 771-772. 10.1002/ajh.21544.CrossRefPubMed

Scuccimarri R, Rohlicek C, Watanabe Duffy KN: Incidence of early cardiac abnormalities in children with Kawasaki Disease treated with low dose aspirin and intravenous immunoglobulin in the acute phase. Arthritis Rheum. 2001, 44 (9):

Salama A, Mueller-Eckhardt C, Kiefel V: Effect of intravenous immunoglobulins in immune thrombocytopenia. Lancet. 1983, 2: 193-195.CrossRefPubMed

10.

Kahwaji J, Barker E, Pepkowitz S: Acute hemolysis after high-dose intravenous Immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol. 2009, 4: 1993-1997. 10.2215/CJN.04540709.PubMedCentralCrossRefPubMed

11.

Pendergrast JM, Pavenski K, Hannach B: Does deficiency of plasma A/B substances increase the risk of IVIG-mediated hemolysis?. Transfusion. 2007, 47: S3-10.1111/j.1537-2995.2007.01303.x.CrossRef

12.

Bunin NJ, Caret JL, Sullivan DB: Autoimmune hemolytic anemia in association with Kawasaki disease. Am J Pediatr Hematol Oncol. 1986, 8: 351-352. 10.1097/00043426-198624000-00019.CrossRefPubMed

13.

Punzarino V, Estrada J, Benson K: Autoimmune hemolytic anemia after Kawasaki disease in a child. Int J Hematol. 1993, 57: 259-263.

14.

Kessary-Shoham H, Levy Y, Shoenfeld Y: In vivo administration of intravenous immunoglobulin can lead to enhanced erythrocyte sequestration. J Autoimmun. 1999, 13: 129-135. 10.1006/jaut.1999.0302.CrossRefPubMed

15.

Saxon B, Hume H, Delage G: Severity of haemolysis following IVIG infusions in Canada. Transfus Med. 2007, 17: 240

Title: Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases
Authors: Roberta Berard
Blair Whittemore
Rosie Scuccimarri
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Pediatric Rheumatology / Issue 1/2012
Electronic ISSN: 1546-0096
DOI: https://doi.org/10.1186/1546-0096-10-10

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases

Abstract

Background

Findings

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Findings

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Giant coronary artery aneurysms in juvenile polyarteritis nodosa: a case report

The role of benign joint hypermobility in the pain experience in Juvenile Fibromyalgia: an observational study

Policy challenges for the pediatric rheumatology workforce

Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis

Differential manifestations of prepubescent, pubescent and postpubescent pediatric patients with systemic lupus erythematosus: A retrospective study of 96 Chinese children and adolescents

Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study